Tumor-associated antigen-specific T cell activation via xenoantigen presentation

Tumor-associated antigen-specific T cell activation via xenoantigen presentation refers to an **immunotherapeutic strategy** rather than a discrete molecular target. In this approach, **xenogeneic forms** of tumor-associated antigens—proteins from another species that are homologous but not identical to human proteins—are introduced into the body, often using dendritic cells or engineered mesenchymal stromal cells. The goal is to break immune tolerance against weakly immunogenic self-antigens expressed by tumors. By presenting these foreign-yet-similar antigens ("xenoantigens"), the immune system can be primed to recognize both the xenogeneic protein and its human counterpart on cancer cells. This method has been shown in clinical studies—for example, using mouse prostatic acid phosphatase in prostate cancer patients—to induce robust **T cell responses** against both the foreign and native versions of the antigen. This can lead to clinically significant anti-tumor effects through enhanced cytotoxicity mediated by CD8+ cytotoxic T lymphocytes and helper functions from CD4+ T cells[2]. Recent research also explores forced intracellular degradation of xenoantigens within engineered vaccine platforms like MSCs, further enhancing peptide presentation on MHC molecules for potent anti-tumoral immunity when combined with checkpoint blockade therapies such as anti-PD1 antibodies[4][5]. However, because this entry describes an *immune mechanism* rather than a specific protein/receptor/enzyme/transporter/etc., it does not fit standard definitions for therapeutic targets used in drug discovery databases. It should be classified as "incorrect" if strict molecular targeting information is required. In summary: This term describes an innovative immunotherapy technique leveraging cross-species antigenicity for cancer treatment—not a canonical molecular target suitable for structured drug-target databases[2][4][5].

Other names

Xenoantigen-based T cell activationXenoantigen vaccination for tumor antigensTumor antigen cross-presentation via xenoantigens

The mechanism involves breaking immune tolerance by presenting xenogeneic forms of tumor antigens to activate T cells against self-tumor antigens.